Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.1K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.1K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

4.2K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.2K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

428
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
428
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

474
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
474
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

1.0K
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.0K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mineralocorticoid receptor antagonists in managing hypertension: a link with diurnal patterns of blood pressure.

Journal of cardiovascular pharmacology·2026
Same author

ADAM17 as a promising molecular target for organ protection in antihypertensive therapy.

American journal of hypertension·2026
Same author

Landiolol in patients with supraventricular arrhythmias: real-world efficacy and safety.

European heart journal. Acute cardiovascular care·2026
Same author

Retraction: The utility of biomarker risk prediction score in patients with chronic heart failure.

Clinical hypertension·2026
Same author

Early predictors of carotid atherosclerosis in patients with type 2 diabetes mellitus.

World journal of diabetes·2025
Same author

New Cardioprotective Frontiers in Double Inhibition With SGLT2 and PCSK9 in Cancer Survivors.

Journal of cardiovascular pharmacology·2025

Related Experiment Video

Updated: Feb 28, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.1K

Microparticles in Chronic Heart Failure.

Alexander E Berezin1

  • 1State Medical University of Zaporozhye, Zaporozhye, Ukraine.

Advances in Clinical Chemistry
|June 21, 2017
PubMed
Summary
This summary is machine-generated.

Microparticles (MPs) are implicated in heart failure (HF) development and progression. Research is exploring their role in HF diagnosis, prognosis, and potential as drug delivery vehicles for cardiac repair.

Keywords:
DiagnosisHFpEFHFrEFHeart failureMicroparticlesPrediction

More Related Videos

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.4K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.1K

Related Experiment Videos

Last Updated: Feb 28, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.1K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.4K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.1K

Area of Science:

  • Cardiovascular Medicine
  • Biomedical Research
  • Pathophysiology

Background:

  • Heart failure (HF) significantly impacts morbidity, mortality, and disability globally.
  • Microparticles (MPs) are increasingly recognized for their roles in thrombosis, coagulation, inflammation, and immunity.
  • MPs may play a crucial role in the pathogenesis and progression of heart failure.

Purpose of the Study:

  • To review the current understanding of various MPs in the diagnosis and prognosis of HF.
  • To explore the potential of MP signatures for predicting HF development and outcomes.
  • To consider the application of MPs as drug delivery systems for attenuating cardiac remodeling.

Main Methods:

  • Literature review and synthesis of existing research on microparticles and heart failure.
  • Analysis of data on the predictive value of circulating MP levels and signatures in HF patients.
  • Examination of studies investigating the role of MP phenotypes in HF pathogenesis.

Main Results:

  • Growing evidence supports the involvement of MPs in multiple pathophysiological processes relevant to HF.
  • Circulating MP levels show predictive value in HF, though MP signatures require further confirmation for clinical utility.
  • The immune phenotype of MPs may be important for HF prediction and development, warranting further investigation.

Conclusions:

  • Microparticles are integral to heart failure pathogenesis and progression.
  • Further research is needed to validate the diagnostic and prognostic utility of specific MP signatures in HF.
  • MPs hold promise as targeted drug delivery vehicles for therapeutic interventions in heart failure.